ngµç×ÓÓÎÏ·ÐÂÎÅÍøѶ£¨Í¨Ñ¶Ô±£ºÀèÎÄÐÅ£©11ÔÂ18ÈÕ£¬£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚ°ËÒ½ÔºÐÄѪ¹ÜÄڿƻƻԽÌÊÚÍŶÓÔÚJournal of Clinical Investigation£¨IF=14.808£©ÉϽÒÏþÁËÌâΪ¡°SIRT6 protects vascular smooth muscle cell from osteogenic transdifferentiation via Runx2 in chronic kidney disease¡±µÄÎÄÕ£¬£¬£¬¸ÃÎÄ̽ÌÖÁËSIRT6ÔÚCKDËùÖÂѪ¹Ü¸Æ»¯ÖеÄ×÷Óü°·Ö×Ó»úÖÆ¡£¡£¡£

Ѫ¹Ü¸Æ»¯£¨Vascular Calcification£¬£¬£¬VC£©ÌØÊâÊÇѪ¹ÜÖÐĤ¸Æ»¯ÔÚÂýÐÔÉöÔಡ£¡£¡£¨Chronic Kidney Disease£¬£¬£¬CKD£©»¼ÕßÖкÜÊÇÆձ飬£¬£¬Ò²ÊÇCKDÐÄѪ¹ÜÊÂÎñ¸ß·¢µÄÖ÷ÒªÔªÐ×£¬£¬£¬Ò»µ©·ºÆðÍùÍùÒâζ׎ϲîµÄÔ¤ºó¡£¡£¡£È»¶ø£¬£¬£¬Æù½ñΪֹ£¬£¬£¬Æä·¢²¡»úÖÆÈÔ²»ÇåÎú£¬£¬£¬ÁÙ´²ÉÏȱ·¦ÓÐÓõÄÖÎÁÆ·½°¸¡£¡£¡£

Sirtuins (SIRTs)ÊÇÒ»ÖÖÊؾɵÄNAD+ÒÀÀµµÄÂÑ°×È¥ÒÒõ£»£»£»¯Ã¸£¬£¬£¬¶ÔÐàÂõºÍ´úлÐÔ¼²²¡Óб£»£»£»¤×÷Ó㬣¬£¬±»ÒÔΪÊÇÐÄѪ¹Ü¼²²¡µÄÖ÷Òª°Ðµã¡£¡£¡£ËüÃÇ¿ÉÒÔά³ÖÄÚƤϸ°ûµÄÎÈ̬¹¦Ð§£¬£¬£¬ÑÓ»ºÑª¹ÜÐàÂõ£¬£¬£¬±£»£»£»¤Ðļ¡Ï¸°û·ÀÖ¹Ðļ¡Ï¸°û·Ê´ó¡£¡£¡£SIRTsÔÚCKDÏà¹ØµÄÐÄѪ¹Ü¼²²¡ÖÐÒ²Óб£»£»£»¤×÷Ó㬣¬£¬µ«ÆäÔÚѪ¹Ü¸Æ»¯ÖеÄ×÷Óü°»úÖÆÈÔÓдýÃ÷È·¡£¡£¡£³É¹Çϸ°ûÌØÒìÐÔת¼Òò×Ó2 (runt-related transcription factor 2,RUNX2£©ÊÇÒ»ÖֳɹǷֻ¯ÌØÒìÐÔת¼Òò×Ó, Äܹ»µ÷¿ØÖÚ¶à»ùÒòµÄת¼£¬£¬£¬¶Ô³É¹Çϸ°ûµÄ·Ö»¯ºÍÈí¹Çϸ°ûµÄ³ÉÊìÆðµ½ÖÁ¹ØÖ÷ÒªµÄ×÷Óᣡ£¡£

×÷ÕßÊ×ÏÈ´ÓÁÙ´²½Ç¶ÈÈëÊÖ£¬£¬£¬·¢Ã÷°éÓÐѪ¹Ü¸Æ»¯µÄCKD²¡ÈËÍâÖÜѪµ¥¸öºËϸ°ûÖеÄSIRT6 mRNAˮƽÒÔ¼°×Ô¶¯Âö×éÖ¯SIRT6ÂÑ°×ˮƽÏÔÖøµÍÓÚ²»°éÓÐѪ¹Ü¸Æ»¯µÄCKD²¡ÈË£¬£¬£¬Í¬Ê±SIRT6µÄ±í´ïˮƽÓë¸Æ»¯AgatstonÆÀ·Ö³Ê¸ºÏà¹Ø£º¸Æ»¯ÆÀ·ÖÔ½¸ßµÄ»¼ÕßSIRT6µÄ±í´ïˮƽԽµÍ¡£¡£¡£Ëæºó£¬£¬£¬×÷Õß¹¹½¨¸ßÏÙàÑßʸßÁ×ÒûʳCKDСÊóÄ£×ÓÓë5/6ÉöÇгýÊõCKDÄ£×ÓÀ´ÓÕµ¼Ñª¹Ü¸Æ»¯£¬£¬£¬Ð§¹ûÏÔʾ¸Æ»¯Ð¡Êó×Ô¶¯ÂöSIRT6±í´ïˮƽÏÔÖø½µµÍ¡£¡£¡£

ΪÁË̽ÌÖSIRT6ÔÚѪ¹Ü¸Æ»¯ÖеÄ×÷Ó㬣¬£¬×÷ÕßÖƱ¸ÁËSIRT6ת»ùÒò£¨SIRT6-Tg£©Ð¡Ê󣬣¬£¬ÒÔ¼°¹¹½¨ÁËѪ¹Üƽ»¬¼¡ÌØÒìÐÔSIRT6ÇüõAAV-2ÏÙÏà¹Ø²¡¶¾£¬£¬£¬Í¬Ê±ÌáÈ¡ÁËСÊóÔ­´úѪ¹Üƽ»¬¼¡Ï¸°û£¨VSMCs£©¡£¡£¡£Í¨¹ýÌåÄÚÓëÌåÍâ¹ý±í´ïÓëÇõÍSIRT6£¬£¬£¬Ö¤Êµ¹ý±í´ïSIRT6Äܹ»Ôڸƻ¯´Ì¼¤Ìõ¼þÏÂïÔÌ­×Ô¶¯Âö×éÖ¯ÓëVSMCsµÄ¸ÆÑγÁ»ý£¬£¬£¬Æðµ½±£»£»£»¤×÷Ó㻣»£»¶øÇüõSIRT6Ôò»á¼ÓÖØѪ¹Ü¸Æ»¯¡£¡£¡£

VSMCsµÄ³É¹Ç·Ö»¯ÔÚѪ¹Ü¸Æ»¯ÖÐÆ𵽺ÜÊÇÖ÷ÒªµÄ×÷Ó㬣¬£¬ÎªÁ˽øÒ»²½Ì½ÌÖSIRT6µ÷¿Ø¸Æ»¯µÄ»úÖÆ£¬£¬£¬×÷Õß¼ì²âÁ˹ý±í´ïÓëÇõÍSIRT6Ö®ºó£¬£¬£¬Ò»Ð©³É¹Ç·Ö»¯ÓëËõ¶Ì±íÐͱê¼ÇÂѰ׵ıí´ïת±ä£¬£¬£¬Ð§¹ûÏÔʾ¹ý±í´ïSIRT6Äܹ»ÒÖÖÆVSMCsµÄ³É¹Ç·Ö»¯¡£¡£¡£Runx2ÊÇÖ÷ÒªµÄ³É¹ÇÒò×Ó£¬£¬£¬SIRT6-TgСÊóÖÐRunx2ÂÑ°×±í´ï½µµÍ£¬£¬£¬¶ø¹ý±í´ïRunx2ºóÄܹ»²¿·ÖÏ÷ÈõSIRT6µÄ±£»£»£»¤×÷Ó㬣¬£¬Òò¶ø×÷ÕßÍƲâSIRT6¿ÉÄÜͨ¹ýµ÷¿ØRunx2À´Ê©Õ¹ÆäÔÚѪ¹Ü¸Æ»¯Öеı£»£»£»¤×÷Óᣡ£¡£Co-IPʵÑé֤ʵ£¬£¬£¬SIRT6ÓëRunx2Ö®¼ä±£´æÏ໥×÷Óᣡ£¡£¶ÔRunx2µÄÒÒõ£»£»£»¯Ë®Æ½¾ÙÐмì²â·¢Ã÷£¬£¬£¬SIRT6¹ý±í´ïÄܹ»ïÔÌ­Runx2µÄÒÒõ£»£»£»¯Ë®Æ½£¬£¬£¬ÇõÍSIRT6ÔòÄÜÔöÌíRunx2µÄÒÒõ£»£»£»¯£¬£¬£¬Åú×¢SIRT6Äܹ»Í¨ÒÑÍùÒÒõ£»£»£»¯Runx2À´ÒÖÖÆƽ»¬¼¡Ï¸°ûµÄ³É¹Ç·Ö»¯¡£¡£¡£¹ý±í´ïSIRT6Äܹ»½µµÍRunx2µÄÂÑ°×ÎȹÌÐÔ£¬£¬£¬½øÒ»²½µÄʵÑé֤ʵSIRT6Äܹ»Í¨¹ý·ºËØ-ÂÑ°×øÌå;¾¶½µ½âRunx2¡£¡£¡£

ÃâÒßÓ«¹âЧ¹ûÏÔʾ£¬£¬£¬¹ý±í´ïSIRT6µÄVSMCsÔÚ¸ßPi´Ì¼¤Ï£¬£¬£¬Ï¸°ûÖÊÖеÄRunx2ÏÔ×ŶàÓÚϸ°ûºË£¬£¬£¬ÌáÐÑSIRT6¿ÉÄÜÓ°ÏìÁËRunx2µÄϸ°ûÄÚ¶¨Î»¡£¡£¡£Exportin-1£¨XPO1£©ÔÚÂѰ׺ËÖÊÊä³öÖÐÆðÖ÷Òª×÷Ó㬣¬£¬IPЧ¹ûÏÔʾXPO1Äܹ»ÓëRunx2Ö±½ÓÁ¬Ïµ£¬£¬£¬¶øÇõÍXPO1Äܹ»ÔöÌíÒò¹ý±í´ïSIRT6Ëùµ¼ÖµÄRunx2µÄÎȹÌÐÔ½µµÍ¡£¡£¡£½øÒ»²½Ó¦ÓÃXPO1ÒÖÖƼÁ£¨Leptomycin A£©ÏÔʾ£¬£¬£¬XPO1ÒÖÖƼÁÄܹ»ÏÔ׿ÓÖعý±í´ïSIRT6Ëùµ¼Öµĸƻ¯¼õÇᣬ£¬£¬ÌáÐÑXPO1ÔÚSIRT6Ëù½éµ¼µÄ¸Æ»¯±£»£»£»¤ÖÐÆðµ½Ö÷Òª×÷Óᣡ£¡£

×ÛÉÏËùÊö£¬£¬£¬¸ÃÎÄÕÂÌá³öÁËSIRT6Äܹ»ÔÚCKDËùÖÂѪ¹Ü¸Æ»¯ÖÐÆð±£»£»£»¤×÷Ó㬣¬£¬·¢Ã÷ÁËSIRT6ͨÒÑÍùÒÒõ£»£»£»¯Runx2£¬£¬£¬Ôö½øRunx2ͨ¹ýXPO1ÒÀÀµµÄ·½Ê½³öºË£¬£¬£¬½ø¶øͨ¹ý·ºËØ-ÂÑ°×øϵһÇнµ½âRunx2£¬£¬£¬´Ó¶øÆðµ½½µµÍVSMCsµÄ³É¹Ç·Ö»¯ÓëÒÖÖÆѪ¹Ü¸Æ»¯µÄ×÷Óᣡ£¡£¸ÃÑо¿Õ¹ÏÖÁËCKD»¼Õß±¬·¢Ñª¹Ü¸Æ»¯µÄ¼ÍÂɺÍÓ°ÏìÒòËØ£¬£¬£¬ÆÊÎöÁËSIRT6½éµ¼µÄRunx2·­ÒëºóÐÞÊÎÔÚѪ¹Ü¸Æ»¯ÖеÄ×÷Ó㬣¬£¬²¢½øÒ»²½ÐðÊöÁ˳¤ÊÙÂÑ°×SIRT6ÖÎÁÆѪ¹Ü¸Æ»¯µÄÐÂDZÄÜ£¬£¬£¬ÎªÆäÁÙ´²·ÀÖÎÌṩÁËеĸÉÔ¤°ÐµãÓëÕ½ÂÔ¡£¡£¡£

¸ÃÂÛÎĵĵÚÒ»×÷ÕßÊÇngµç×ÓÓÎÏ·Á¥ÊôµÚ°ËÒ½ÔºÀèÎÄÐŲ©Ê¿£¬£¬£¬Á¥ÊôµÚ°ËÒ½Ôº»Æ»Ô½ÌÊÚΪ¸ÃÎÄÕµÄ×ÔÁ¦Í¨Ñ¶×÷Õß¡£¡£¡£¸ÃÑо¿»ñµÃÁ˹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿£¨Åú×¼ºÅ£º8201101103, 81870506, 91849208£¬£¬£¬81670676£©µÈϵÁÐ×ÊÖú¡£¡£¡£Í¬Ê±ÉîÛÚ´óѧÁõ±¦»ª½ÌÊÚ£¬£¬£¬ÄÏ·½Ò½Ôº·ëΰ¾µ£¬£¬£¬ngµç×ÓÓÎÏ·¶«»ªÒ½ÔºËÕÏþÑàºÍngµç×ÓÓÎÏ·Á¥ÊôµÚ°ËÒ½ÔºÂÞ¶¬Áᣬ£¬£¬ÎªÂÛÎÄ×öÁËÖ÷ҪТ˳¡£¡£¡£

ÂÛÎÄÁ´½Ó£ºhttps://www.jci.org/articles/view/150051